Macquarie has downgraded Dr. Reddy’s Laboratories to a Neutral rating due to concerns over gRevlimid. This shift signals potential challenges ahead for the pharmaceutical company and could influence investor decisions.

Nvidia’s stock experienced a decline after the company openly criticized President Biden’s policy on China chip restrictions. The tech giant’s stance highlights rising tensions between technology companies and government policies affecting international trade.